BR112018006339A2 - método de avaliação da normalidade do repertório imunológico e seu uso - Google Patents

método de avaliação da normalidade do repertório imunológico e seu uso

Info

Publication number
BR112018006339A2
BR112018006339A2 BR112018006339A BR112018006339A BR112018006339A2 BR 112018006339 A2 BR112018006339 A2 BR 112018006339A2 BR 112018006339 A BR112018006339 A BR 112018006339A BR 112018006339 A BR112018006339 A BR 112018006339A BR 112018006339 A2 BR112018006339 A2 BR 112018006339A2
Authority
BR
Brazil
Prior art keywords
immune repertoire
normality
assessing
diversity
individuals
Prior art date
Application number
BR112018006339A
Other languages
English (en)
Inventor
Han Jian
Original Assignee
Irepertoire Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irepertoire Inc filed Critical Irepertoire Inc
Publication of BR112018006339A2 publication Critical patent/BR112018006339A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

a presente revelação pertence geralmente a um método para comparação da diversidade do repertório imunológico de um paciente com o repertório imunológico compartilhado de um grupo de indivíduos para identificar se a diversidade do repertório imunológico do paciente é normal ou anormal em relação ao repertório imunológico compartilhado do grupo de indivíduos.
BR112018006339A 2015-09-29 2016-09-29 método de avaliação da normalidade do repertório imunológico e seu uso BR112018006339A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562234424P 2015-09-29 2015-09-29
PCT/US2016/054469 WO2017059084A1 (en) 2015-09-29 2016-09-29 Immunorepertoire normality assessment method and its use

Publications (1)

Publication Number Publication Date
BR112018006339A2 true BR112018006339A2 (pt) 2018-10-16

Family

ID=58406740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018006339A BR112018006339A2 (pt) 2015-09-29 2016-09-29 método de avaliação da normalidade do repertório imunológico e seu uso

Country Status (11)

Country Link
US (1) US11047011B2 (pt)
EP (1) EP3356976A4 (pt)
JP (1) JP2018531044A (pt)
KR (1) KR20180054829A (pt)
CN (2) CN108513660A (pt)
AU (2) AU2016330780A1 (pt)
BR (1) BR112018006339A2 (pt)
CA (1) CA2997787A1 (pt)
HK (1) HK1257433A1 (pt)
RU (1) RU2766004C1 (pt)
WO (1) WO2017059084A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. HPV-SPECIFIC BINDING MOLECULES
EP3694872A4 (en) * 2017-10-12 2021-06-30 Board Of Regents, The University Of Texas System T-CELL RECEPTORS FOR IMMUNOTHERAPY
MX2020010460A (es) 2018-04-05 2021-01-29 Juno Therapeutics Inc Receptores de células t, y células diseñadas que expresan los mismos.
NL2021034B1 (en) * 2018-05-31 2019-12-10 Academisch Ziekenhuis Leiden TEIPP neoantigens and uses thereof
EP3908678A1 (en) 2019-01-10 2021-11-17 Iovance Biotherapeutics, Inc. System and methods for monitoring adoptive cell therapy clonality and persistence
AU2020237043A1 (en) * 2019-03-11 2021-09-30 Fred Hutchinson Cancer Center High avidity WT1 T cell receptors and uses thereof
EP3760217A1 (en) * 2019-07-01 2021-01-06 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Cd5 specific t cell receptor cell or gene therapy
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN116836261A (zh) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 一种识别mage-a4抗原的高亲和力tcr及其序列和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999092B2 (en) * 2008-04-03 2011-08-16 Hudsonalpha Institute For Biotechnology Amplicon rescue multiplex polymerase chain reaction for amplification of multiple targets
US9012148B2 (en) * 2008-04-16 2015-04-21 Jian Han Method for evaluating and comparing immunorepertoires
WO2011140433A2 (en) * 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Measurement and comparison of immune diversity by high-throughput sequencing
WO2012097374A1 (en) 2011-01-14 2012-07-19 Cb Biotechnologies, Inc. Immunodiversity assessment method and its use
CN103184216B (zh) * 2011-12-27 2015-03-18 深圳华大基因科技有限公司 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途
WO2014121272A2 (en) * 2013-02-04 2014-08-07 Quake Stephen R Measurement and comparison of immune diversity by high-throughput sequencing
JP6460343B2 (ja) 2013-02-11 2019-01-30 アイレパートリー インコーポレイテッド 免疫レパートリーを評価するための方法
US20160091491A1 (en) 2013-05-02 2016-03-31 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosis of celiac disease

Also Published As

Publication number Publication date
US20170088895A1 (en) 2017-03-30
JP2018531044A (ja) 2018-10-25
WO2017059084A8 (en) 2018-04-19
CN108513660A (zh) 2018-09-07
US11047011B2 (en) 2021-06-29
HK1257433A1 (zh) 2019-10-18
EP3356976A4 (en) 2019-03-13
KR20180054829A (ko) 2018-05-24
WO2017059084A1 (en) 2017-04-06
CA2997787A1 (en) 2017-04-06
EP3356976A1 (en) 2018-08-08
CN115572760A (zh) 2023-01-06
AU2021290268A1 (en) 2022-01-27
RU2766004C1 (ru) 2022-02-07
AU2016330780A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
BR112018006339A2 (pt) método de avaliação da normalidade do repertório imunológico e seu uso
BR112016004305A2 (pt) métodos diagnósticos e composições para tratamento de glioblastoma
BR112017009004A2 (pt) composições e métodos compreendendo bactérias para melhorar o comportamento em distúrbios do desenvolvimento neurológico
BR112016029226A2 (pt) métodos e composições para o tratamento de úlceras
WO2016040775A8 (en) Apparatus and methods for identifying and evaluating bright spot indications observed through optical coherence tomography
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
BR112017008284A2 (pt) bifidobactérias ativadas e métodos para uso das mesmas
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
BR112019009256A2 (pt) métodos para tratar síndrome de alport usando bardoxolona metil ou análogos do mesmo
BR112016023720A2 (pt) nebulizador
BR102015017380A2 (pt) dispositivo para a reticulação do tecido do olho, e, composição farmacêutica
BR112016021383A2 (pt) Método para identificar um paciente com câncer que é susceptível ou menos susceptível a responder ao tratamento com um antagonista de cmet, método para identificar um paciente apresentando câncer previamente tratado, método para determinar a expressão do biomarcador hgf, antagonista anti-c-met e seu uso, kit de diagnóstico e seu método de preparo
BR112016025470A2 (pt) ?hdl terapêutico?
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
BR112017022206A2 (pt) fluxograma de atendimento, mecanismo, plataforma, dispositivo, sistema, método e meio legível por computador sensíveis ao contexto
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112018013272A2 (pt) composições e métodos para detectar e tratar câncer esofágico
BR112016023754A2 (pt) ?uso de lactobacillus paracasei para promover recuperação da diversidade da microbiota intestinal após disbiose?
BR112017015159A2 (pt) preparação e uso de produtos plaquetários
GB2567326B (en) Multi-fiber optical probe and optical coherence tomography system
BR112012032389A2 (pt) biomarcadores para a previsão de câncer incidente
BR112018013268A2 (pt) composições e métodos para detectar e tratar câncer gástrico
BR112015022513A2 (pt) produto e método para tratamento de diarreia
BR112012023747A2 (pt) compostos de adenosina e seu uso

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time